To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:3 Issue:4 Number:65 ISSN#:2564-2537
ACE Report #6010
Ace Report Cover Tumour

Oral ibandronic acid inferior to IV zoledronic acid for metastatic breast cancer to bone

How to Cite

OrthoEvidence. Oral ibandronic acid inferior to IV zoledronic acid for metastatic breast cancer to bone. ACE Report. 2014;3(4):65. Available from:

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial

Lancet Oncol. 2014 Jan;15(1):114-22. doi: 10.1016/S1470-2045(13)70539-4.

Contributing Authors:
P Barrett-Lee A Casbard J Abraham K Hood R Coleman P Simmonds H Timmins D Wheatley R Grieve G Griffiths N Murray

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


1404 patients with bone metastases from breast cancer were randomized to receive treatment with either oral ibandronic acid or intravenous zoledronic acid. The frequency and timing of skeletal-related events (SREs) was the primary non-inferiority endpoint. After 96 weeks of treatment, 50 mg of oral ibandronic acid given daily was inferior to 4 mg of intravenous zoledronic acid given every 4 weeks ...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.